Teva Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Teva Pharma (TEVA) Tops Q1 EPS by 4c, Revenues Miss; Offers FY21 EPS/Revenue Guidance
April 28, 2021 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q1 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $3.98 billion versus the consensus estimate of $4.02 billion.
Revenues of $4.0 billionGAAP diluted EPS of $0.07Non-GAAP diluted EPS of... More


